ArticlePathogens (Basel, Switzerland)2025
Systemic Inflammation and Gastrointestinal Complications in HIV Patients: A Cross-Sectional Study on the Role of Type II Diabetes.
Article in Pathogens (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
(1) Background: This study aimed to assess the association between inflammatory biomarkers and gastrointestinal side effects in HIV-positive patients on antiretroviral therapy (ART), with a specific focus on the impact of type II diabetes. (2) Methods: A total of 320 participants were divided into three groups: 120 HIV-positive without diabetes, 80 HIV-positive with type II diabetes, and 120 controls. Biomarkers such as CRP, IL-6, and TNF-α, along with gastrointestinal symptoms, were measured before and six months after ART. (3) Results: HIV-positive patients with type II diabetes exhibited significantly elevated levels of inflammatory markers and experienced more frequent gastrointestinal side effects, particularly nausea and diarrhea. (4) Conclusions: Type II diabetes significantly worsens inflammation and gastrointestinal side effects in HIV patients on ART, suggesting the need for tailored treatment approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.